• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Implications for practice: phase II/III trial of carboplatin and irinotecan for elderly patients with extensive-stage small-cell lung cancer in Japan.

作者信息

Maheshwari Shipra, Gentzler Ryan D

机构信息

Division of Hematology, Department of Medicine, University of Virginia Cancer Center, Charlottesville, VA, USA.

出版信息

J Thorac Dis. 2024 Sep 30;16(9):6342-6346. doi: 10.21037/jtd-24-279. Epub 2024 Sep 23.

DOI:10.21037/jtd-24-279
PMID:39444913
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11494565/
Abstract
摘要

相似文献

1
Implications for practice: phase II/III trial of carboplatin and irinotecan for elderly patients with extensive-stage small-cell lung cancer in Japan.实践意义：日本针对广泛期小细胞肺癌老年患者开展的卡铂和伊立替康II/III期试验
J Thorac Dis. 2024 Sep 30;16(9):6342-6346. doi: 10.21037/jtd-24-279. Epub 2024 Sep 23.
2
Carboplatin and irinotecan (CI) vs. carboplatin and etoposide (CE) for the treatment of extended-stage small-cell lung cancer in an elderly population: A phase II/III randomized control trial.卡铂和伊立替康（CI）与卡铂和依托泊苷（CE）治疗老年广泛期小细胞肺癌：一项 II/III 期随机对照临床试验。
Lung Cancer. 2023 Jul;181:107195. doi: 10.1016/j.lungcan.2023.107195. Epub 2023 Apr 22.
3
A Phase II/III study comparing carboplatin and irinotecan with carboplatin and etoposide for the treatment of elderly patients with extensive-disease small-cell lung cancer (JCOG1201).一项比较卡铂联合伊立替康与卡铂联合依托泊苷治疗广泛期小细胞肺癌老年患者的II/III期研究（JCOG1201）。
Jpn J Clin Oncol. 2015 Jan;45(1):115-8. doi: 10.1093/jjco/hyu166. Epub 2014 Oct 20.
4
A combination chemotherapy of carboplatin and irinotecan with granulocyte colony-stimulating factor (G-CSF) support in elderly patients with small cell lung cancer.卡铂和伊立替康联合化疗并给予粒细胞集落刺激因子（G-CSF）支持治疗老年小细胞肺癌患者。
Lung Cancer. 2006 Aug;53(2):197-203. doi: 10.1016/j.lungcan.2006.05.004. Epub 2006 Jun 15.
5
A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer.伊立替康联合卡铂与依托泊苷联合卡铂治疗广泛期小细胞肺癌患者的随机II期试验。
Ann Oncol. 2006 Apr;17(4):663-7. doi: 10.1093/annonc/mdj137. Epub 2006 Jan 19.
6
Phase I/II study of induction chemotherapy using carboplatin plus irinotecan and sequential thoracic radiotherapy (TRT) for elderly patients with limited-disease small-cell lung cancer (LD-SCLC): TORG 0604.卡铂联合伊立替康诱导化疗及序贯胸部放疗（TRT）用于老年局限性小细胞肺癌（LD-SCLC）患者的I/II期研究：TORG 0604
BMC Cancer. 2017 May 26;17(1):377. doi: 10.1186/s12885-017-3353-y.
7
Phase II study of IRInotecan treatment after COmbined chemo-immunotherapy for extensive-stage small cell lung cancer: Protocol of IRICO study.广泛期小细胞肺癌联合化疗免疫治疗后伊立替康治疗的 II 期研究：IRICO 研究方案。
Thorac Cancer. 2023 Oct;14(28):2890-2894. doi: 10.1111/1759-7714.15097. Epub 2023 Sep 7.
8
A phase II study of carboplatin and etoposide plus durvalumab for previously untreated extensive-stage small-cell lung cancer (ES-SCLC) patients with a poor performance status (PS): NEJ045A study protocol.一项 II 期研究，评估卡铂和依托泊苷联合度伐利尤单抗治疗体能状态较差（PS）的未经治疗的广泛期小细胞肺癌（ES-SCLC）患者的疗效：NEJ045A 研究方案。
BMC Cancer. 2022 Nov 4;22(1):1135. doi: 10.1186/s12885-022-10222-1.
9
Should irinotecan or etoposide be used in combination with carboplatin for small cell lung cancer?伊立替康或依托泊苷应与卡铂联合用于小细胞肺癌吗？
Nat Clin Pract Oncol. 2009 Mar;6(3):134-5. doi: 10.1038/ncponc1324. Epub 2009 Jan 20.
10
A feasibility study of carboplatin plus irinotecan treatment for elderly patients with extensive disease small-cell lung cancer.卡铂联合伊立替康治疗广泛期老年小细胞肺癌的可行性研究。
Jpn J Clin Oncol. 2014 Feb;44(2):116-21. doi: 10.1093/jjco/hyt195. Epub 2013 Dec 13.

本文引用的文献

1
Carboplatin and irinotecan (CI) vs. carboplatin and etoposide (CE) for the treatment of extended-stage small-cell lung cancer in an elderly population: A phase II/III randomized control trial.卡铂和伊立替康（CI）与卡铂和依托泊苷（CE）治疗老年广泛期小细胞肺癌：一项 II/III 期随机对照临床试验。
Lung Cancer. 2023 Jul;181:107195. doi: 10.1016/j.lungcan.2023.107195. Epub 2023 Apr 22.
2
A Geriatric Assessment Intervention to Reduce Treatment Toxicity Among Older Adults With Advanced Lung Cancer: A Subgroup Analysis From a Cluster Randomized Controlled Trial.一项旨在降低晚期肺癌老年患者治疗毒性的老年评估干预措施：一项整群随机对照试验的亚组分析
Front Oncol. 2022 Mar 31;12:835582. doi: 10.3389/fonc.2022.835582. eCollection 2022.
3
Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN.度伐利尤单抗联合或不联合 Tremelimumab 加铂类依托泊苷一线治疗广泛期小细胞肺癌：CASPIAN 的 3 年总生存更新。
ESMO Open. 2022 Apr;7(2):100408. doi: 10.1016/j.esmoop.2022.100408. Epub 2022 Mar 10.
4
Lung Cancer in Japan.日本的肺癌
J Thorac Oncol. 2022 Mar;17(3):353-361. doi: 10.1016/j.jtho.2021.11.020.
5
Extensive-Stage Small-Cell Lung Cancer: First-Line and Second-Line Treatment Options.广泛期小细胞肺癌：一线和二线治疗选择。
J Clin Oncol. 2022 Feb 20;40(6):671-680. doi: 10.1200/JCO.21.01881. Epub 2022 Jan 5.
6
First-line treatment for lung cancer among Japanese older patients: A real-world analysis of hospital-based cancer registry data.日本老年肺癌患者的一线治疗：基于医院癌症登记数据的真实世界分析。
PLoS One. 2021 Sep 20;16(9):e0257489. doi: 10.1371/journal.pone.0257489. eCollection 2021.
7
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities.转录因子程序和免疫途径激活模式定义了具有不同治疗弱点的 SCLC 的四个主要亚型。
Cancer Cell. 2021 Mar 8;39(3):346-360.e7. doi: 10.1016/j.ccell.2020.12.014. Epub 2021 Jan 21.
8
Small-cell lung cancer.小细胞肺癌。
Nat Rev Dis Primers. 2021 Jan 14;7(1):3. doi: 10.1038/s41572-020-00235-0.
9
Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study.帕博利珠单抗或安慰剂联合依托泊苷和铂类药物作为广泛期小细胞肺癌一线治疗：随机、双盲、III 期 KEYNOTE-604 研究。
J Clin Oncol. 2020 Jul 20;38(21):2369-2379. doi: 10.1200/JCO.20.00793. Epub 2020 May 29.
10
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.度伐利尤单抗联合铂类依托泊苷与铂类依托泊苷一线治疗广泛期小细胞肺癌（CASPIAN）：一项随机、对照、开放标签、III 期临床试验。
Lancet. 2019 Nov 23;394(10212):1929-1939. doi: 10.1016/S0140-6736(19)32222-6. Epub 2019 Oct 4.